Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, which will be held September 8 12 in Madrid, Spain. Abstracts are available to the public online on the ESMO website: http://www.esmo.org.

Abstract #1490: Neratinib after trastuzumab-based adjuvant therapy in early stage HER2-positive breast cancer:5-year analysis of the Phase III ExteNET trial.The abstract will be presented as a proffered paper oral session on Friday, September 8.

Abstract #177P:Effects of neratinib on health-related quality of life in early stage HER2-positive breast cancer.The abstract will be displayed as a poster on Monday, September 11.

The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in women with early stage HER2-positive breast cancer.

U.S. Approval of Neratinib (NERLYNX)

Neratinib was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets.

About HER2-Positive Breast Cancer

Approximately 20% to 25% of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.

Indication

NERLYNX is a tyrosine kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance.More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

The full prescribing information for NERLYNX is available at http://www.NERLYNX.com. The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, continuously for one year. Antidiarrheal prophylaxis should be initiated with the first dose of NERLYNX and continued during the first 2 months (56 days) of treatment and as needed thereafter.

Important Safety Information

There are possible side effects of NERLYNX. Patients must contact their doctor right away if they experience any of these symptoms. NERLYNX treatment may be stopped or the dose may be lowered if the patient experiences any of these side effects.

Diarrhea

Diarrheais a common side effect ofNERLYNX. The diarrhea may be severe, and you may get dehydrated. Your healthcare provider should prescribe the medicine loperamide for you during your first 2 cycles (56 days) of NERLYNX and then as needed. To help prevent or reduce diarrhea:

Contact your healthcare provider right away if you have severe diarrhea or if you have diarrhea along with weakness, dizziness or fever.

Liver Problems

Changes in liver function tests are common with NERLYNX. The patients doctor will do tests before starting treatment, monthly during the first 3 months, and then every 3 months as needed during treatment with NERLYNX. NERLYNX treatment may be stopped or the dose may be lowered if your liver tests show severe problems. Symptoms of liver problems may include tiredness, nausea, vomiting, pain in the right upper stomach area (abdomen), fever, rash, itching or yellowing of your skin or whites of your eyes.

Pregnancy

Patients should tell their doctor if they are planning to become pregnant, are pregnant, plan to breastfeed, or are breastfeeding. NERLYNX can harm your unborn baby. Birth control should be used while a patient is receiving NERLYNX and for at least 1 month after the last dose. If patients are exposed to NERLYNX during pregnancy, they must contact their healthcare provider right away.

Common side effects in patients treated with NERLYNX

In clinical studies, the most common side effects seen in patients taking NERLYNX were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis (dry or inflamed mouth, or mouth sores), decreased appetite, muscle spasms, dyspepsia, changes in liver blood test results, nail problems, dry skin, abdominal distention, weight loss and urinary tract infection.

Patients should tell their doctor right away if they are experiencing any side effects. Report side effects to the FDA at 1-800-FDA-1088 orhttp://www.FDA.gov/medwatch. Patients and caregivers may also report side effects to Puma Biotechnology at 1-844-NERLYNX (1-844-637-5969).

Please see Full Prescribing Information, available at http://www.NERLYNX.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. NERLYNX (neratinib) is approved for commercial use by prescription in the United States as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed as NERLYNX. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the commercialization of NERLYNX and the continued development of its other advanced drug candidates directed at the treatment of HER2-positive breast cancer. The Company believes that NERLYNX has clinical application in the potential treatment of several other cancers that over-express or have a mutation in HER2.

Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the benefits of NERLYNX and neratinib, the Companys clinical trials and the announcement of data relative to those trials. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Companys actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has only recently commenced commercialization and shipment of its only FDA approved product; the Companys dependence upon the commercial success of NERLYNX (neratinib); the Companys history of operating losses and its expectation that it will continue to incur losses for the foreseeable future; risks and uncertainties related to the Companys ability to achieve or sustain profitability; the Companys ability to predict its future prospects and forecast its financial performance and growth; failure to obtain sufficient capital to fund the Companys operations; the effectiveness of sales and marketing efforts; the Companys ability to obtain FDA approval or other regulatory approvals in the United States or elsewhere for other indications for neratinib or other product candidates; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Companys drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Companys products; the Companys reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; risks pertaining to securities class action, derivative and defamation lawsuits; the Companys dependence on licensed intellectual property; and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170830006310/en/

Continue reading here:
Puma Biotechnology Announces Publication of Abstracts for ESMO 2017 - Markets Insider

Puma Biotechnology (NYSE:PBYI) is inching closer to its transformation from a research and development (or R&D) biopharmaceutical company to a full-fledged commercial organization. This company which has in-licensed development and commercialization rights for oral and intravenous formulations of irreversible tyrosine kinase inhibitor or TKI, neratinib, and also another irreversible TKI, PB357, achieved the first major milestone for 2017 on May 24, 2017. On this day, FDA's Oncologic Drugs Advisory Committee or ODAC recommended approval for Nerlynx (neratinib) as extended adjuvant therapy for patients suffering with early stage, human epidermal growth factor receptor type 2 - positive or HER2-positive breast cancer after being previously treated with surgery and adjuvant treatment with Roche Holdings' (OTCQX:RHHBY) Herceptin (trastuzumab).

Besides this indication, Puma Biotechnology expects neratinib to demonstrate efficacy in other cancers such a non small cell lung cancer and tumors related to expression or over-mutation in HER2 such as HER2-positive cancer, HER-2 cancer that has metastasized to brain, HER2-positive neoadjuvant breast cancer.

Hence, there is high probability that Neratinib can prove to be a blockbuster drug for Puma Biotechnology. I believe this is a solid reason for considering the company as a favorable investment opportunity in 2017. In this article, I will explain the key drivers that make Puma Biotechnology a compelling investment opportunity in 2017.

Extended adjuvant setting is a larger underserved market segment

Currently, the target breast cancer market in extended adjuvant setting comprises around 36,000 patients in USA and 34,000 in EU. In 2015, Herceptin's sales in adjuvant indication were around $4.5 billion to $5.0 billion. All these patients form a target market for neratinib in the following year. Currently, letrozole is the only FDA approved therapy in extended adjuvant setting.

Puma Biotechnology expects to launch Neratinib as extended adjuvant breast cancer therapy in 2017

In July 2016, Puma Biotechnology filed new drug application or NDA with FDA, seeking approval for neratinib in extended adjuvant setting for early stage HER2-overexpressed/amplified breast cancer. The regulatory agency accepted the application in September 2016.

Further, the European Medicines Agency or EMA also validated Puma's application for neratinib in extended adjuvant setting in August 2016. On advice of EMA, in March 2017, the company revised its label to only include those early stage HER2+ breast cancer patients who had been previously treated for up to 1 year with adjuvant herceptin. Puma Biotechnology initiated a managed access program for neratinib in this indication in Q4 2016 and an expanded access program in Q1 2017.

While all these have been major milestones for the company in the past, the upcoming milestone will be FDA approval for orally administered neratinib in extended adjuvant setting, anticipated in 3Q 2017.

This approval is expected to be mainly based on results obtained from phase 3 trial, ExteNET, in which neratinib managed to hit its primary endpoints. In the intent-to-treat or ITT population, the 2-year disease free survival or DFS in neratinib arm was seen to be 93.9% while that in the placebo arm was 91.6%, which implies absolute improvement of 2.4%. In ITT population, there has been a 2.5% absolute improvement in 5-year DFS for neratinib arm as compared to placebo arm.

In case of patients confirmed with HER+ breast cancer, neratinib demonstrated 2-year DFS of 94.7%, while it was only 90.6% for the placebo arm. While this is an absolute improvement of 4.1%, the 5-year DFS with neratinib in HER+ patients is slightly higher at 4.4%.

Data from ExteNET trial has also shown 33% reduction in risk of disease recurrence for patients in neratinib arm as compared to those in placebo arm in ITT population. Further, for confirmed HER+ early stage breast cancer patients, the reduction in risk of disease recurrence for those on neratinib therapy in extended adjuvant setting is as high as 49%.

All these statistics are in line with those seen for the already approved extended adjuvant breast cancer drug, letrozole, as well as data obtained from development trials for hormone receptor positive or HR+ adjuvant breast cancer therapies, Pfizer's (NYSE:PFE) Aromasin and AstraZeneca's (NYSE:AZN) Arimidex. This implies that there are high chances for neratinib to secure FDA approval in extended adjuvant setting.

Neratinib has demonstrated higher benefit as adjuvant therapy in HR+ breast cancer patients

For HR+ breast cancer patients in ExteNET trial, the adjuvant therapy of neratinib demonstrated DFS rate of 95.4%, while the placebo arm showed DFS of 91.2%. This implied an absolute benefit of 4.2% after 2 years.

For 5-year period, the DFS with neratinib in HR+ patients was 91.7% while that in placebo arm was 86.9%, implying 4.8% absolute benefit.

Neratinib has demonstrated superior results in HR+ patients mainly on account of dual suppression of the crosstalk between estrogen receptor-positive or ER+ and HER+. Since ER+ breast cancer patients in the ExteNET trial were already on background endocrine therapy, it helped suppress the ER while neratinib suppressed both EGFR and HER2. This dual suppression has been seen only in neratinib and not in trials of other breast cancer drugs such Roche Holdings Herceptin and Novartis' (NYSE:NVS) Tykerb.

In case of HR- patients, however, ExteNET trial demonstrated improvement with neratinib between months 0 to 12 as compared to placebo. This was essentially when the patients were being administered the drug. However, the benefit in DFS in the neratinib arm over placebo arm seemed to become statistically insignificant over 5 year horizon.

Puma Biotechnology has also introduced loperamide prophylaxis therapy to prevent diarrhea resulting from neratinib.

Prior to Puma Biotechnology in-licensing Neratinib, it was being tested on 3,000 patients in various trials. It was seen that these patients suffered from grade 3 or grade 4 diarrhea in the first 28 days after initiating therapy. However, this could be treated with antidiarrheal drug, loperamide.

Puma Biotechnology is instead focusing on preventing this side-effect of neratinib using loperamide prophylaxis. Data from multiple studies has shown that the rate of grade 3 diarrhea reduced from the range of 30% to 53% in case of no loperamide prophylaxis to the range of 0% to 17% with loperamide prophylaxis. The total duration of diarrhea also dropped from 14 days to 2 days with loperamide prophylaxis.

Since ExteNET trial did not involve any anti-diarrheal prophylaxis therapy, Puma Biotechnology separately studied the impact of loperamide prophylaxis alone and in combination with other anti-inflammatory agents in extended adjuvant setting in early stage HER2+ breast cancer patients in another phase 2 trial, CONTROL. Data from this trial showed that while rate of grade 3 diarrhea in ExteNET trial was 39.8%, loperamide prophylaxis reduced the rate to 30.7%, loperamide and budesonide prophylaxis to 23.4%, and loperamide and colestipol to 11.5%.

Further, while the duration of diarrhea in ExteNET trial was 59 days, the various prophylaxis regimens in the CONTROL trial have brought the down to the range of 8 to 12 days. Episodes of diarrhea were also brought down from 8 in ExteNET trial to the range of 2 to 4 in CONTROL trial.

The CONTROL trial has also shown improvement in tolerability for the drug, which was being mainly affected due to diarrhea.

All this shows that the major side-effect of Neratinib, diarrhea, is easily manageable with effective prophylaxis therapy. Further, it is only seen that grade 3 diarrhea was witnessed by patients only in first cycle or first 28 days of neratinib therapy.

The company's cash reserves can sustain its operations through mid-2018

At the end of Q1 2017, Puma Biotechnology had $194 million worth cash reserves on its balance sheet. The company's cash burn rate in Q1 2017 was $36.0 million. This can be considered representative for all the quarters in 2017, as Puma has been highly involved in preparing for regulatory approval and commercial launch of neratinib. Based on these assumptions, the company can sustain its business operations upto the first half of 2018, without depending on external funding.

Further, with a solid oncology drug in the pipeline, Puma Biotechnology will also not find it difficult to raise capital from the public, either as equity or debt. Hence, the company seems to be at a comfortable position.

Investors should not ignore certain company-specific risks

Today, Puma Biotechnology is equivalent to neratinib. In absence of any commercial product or advanced stage research product, Puma Biotechnology is excessively dependent on the successful commercial launch of Neratinib. Since the product has not yet received FDA approval for even a single indication, this may prove to be too risky investment for investors with average risk appetite.

Further, the company also does not have proven marketing and distribution capabilities. In absence of a strong commercial partner, Puma Biotechnology may land up being commercially unsuccessful, despite securing FDA approval for neratinib.

Investors should consider these major risk factors while considering Puma Biotechnology as an opportunity in 2017.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Originally posted here:
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity - Seeking Alpha

Cellect Biotechnology

Kfar Saba, Israel-based Cellect Biotechnology Ltd's stock finished Monday's session 2.84% lower at $8.56 with a total trading volume of 27,234 shares. Over the previous three months and since the start of this year, the Company's shares have advanced 34.80% and 177.02%, respectively. The stock is trading above its 200-day moving average by 53.25%. Moreover, shares of Cellect Biotech, which focuses on developing solutions for immune system regeneration in Israel, have a Relative Strength Index (RSI) of 34.93.

On May 23rd, 2017, Cellect Biotech announced that David Braun, Head of Merck Group's Medical Device Business, is joining the Company's Scientific and Medical Advisory Board. Mr. Braun has held multiple additional senior-level executive positions at leading biotech and high-tech companies, ranging from global Fortune 500 corporations to growth-oriented organizations, including Biosafe S.A., a stem cell separation leader recently acquired by GE, Newell Brands, Logitech, Chiaro Networks, and Elbit Systems. Your complete research report on APOP can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=APOP

BioDelivery Sciences

Shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. declined 4.26%, ending yesterday's session at $2.25 with a total trading volume of 405,472 shares. The stock has gained 25.00% in the past month, 9.76% in the previous three months, and 28.57% on an YTD basis. The Company's shares are trading 17.71% above their 50-day moving average and 8.95% above their 200-day moving average. Moreover, shares of BioDelivery Sciences, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have an RSI of 56.49.

On May 26th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $4 per share.

On June 01st, 2017, BioDelivery Sciences announced that Dr. Mark A. Sirgo, President and CEO, will present at the Jefferies 2017 Healthcare Conferenceon June 06th, 2017, at9:30 a.m. ET at the Grand Hyatt in New York City. Dr. Sirgo will focus on progress with commercialization efforts and strategic initiatives supporting BELBUCA(buprenorphine) buccal film (CIII), as well as provide an update on BUNAVAIL(buprenorphine and naloxone) CIII.A free report on BDSI is just a click away at: http://dailystocktracker.com/registration/?symbol=BDSI

BioLine Rx

On Monday, Jerusalem, Israel headquartered BioLine Rx Ltd's stock saw a decline of 2.51%, to close the day at $0.82. A total volume of 177,369 shares was traded. The Company's shares are trading 8.55% below their 50-day moving average. Additionally, shares of BioLine Rx, which engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs, have an RSI of 41.26.

On May 18th, 2017, research firm Maxim Group upgraded the Company's stock rating from 'Hold' to 'Buy' while revising its previous target price from $1 a share to $3 a share.

On June 01st, 2017, BioLine Rx announced that Genentech, a member of the Roche Group, has filed a total of three, regulatory submissions required to commence Phase-1b trials for BL-8040 in combination with atezolizumab (Tecentriq), Genentech's anti-PDL1 cancer immunotherapy, for the treatment of patients with solid tumors. The trials for pancreatic, gastric, and non-small cell cancer are expected to commence during Q2 2017 after receipt of regulatory approval. Sign up for your complimentary research report on BLRX at: http://dailystocktracker.com/registration/?symbol=BLRX

Benitec Biopharma

Shares in North Sydney, Australia headquartered Benitec Biopharma Ltd ended the day 4.02% lower at $2.39. A total volume of 50,220 shares was traded. The stock has gained 56.21% since the start of this year. The Company's shares are trading above their 200-day moving average by 16.27%. Furthermore, shares of Benitec Biopharma, which develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference in Australia, the UK, and the US, have an RSI of 43.99. Register for free on DailyStockTracker.com and download the latest research report on BNTC at: http://dailystocktracker.com/registration/?symbol=BNTC

--

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

DST has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: contact@dailystocktracker.com Phone number: (207)-331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Continued here:
Biotech Stock Performance Review -- Cellect Biotechnology ... - PR Newswire (press release)

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Shares of Puma Biotechnology Inc (PBYI) broke into a new 52-week high yesterday, hitting a peak of $80.20. Shares closed at $76.90 after opening at $80.15 for a move of -3.57%. The company now has a market cap of $2.84 billion.

Investors and traders can learn a lot about a stocks momentum when it sets a new 52-week high. As an example, bullish investors view a company hitting its highest price in a year as a sign of momentum and may interpret it as a signal to buy. On the other hand, bearish investors could view a new 52-week high as a signal of the end of a strong run, with the stock possibly peaking out before an impending period of decline.

For Puma Biotechnology Inc, the new 52-week high came on volume of 1.52 million. The stock has a float of 36.97 million shares and average daily volume of $1.37 million. It has a 50-day SMA of $40.01 and a 200-day SMA of $43.35.

For a complete fundamental analysis analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

Puma Biotechnology Inc is also a component of the Russell 2000 Index, which is an invaluable tool for any small-cap investor. Consisting of the smaller 2,000 publicly traded companies of the 3,000 largest companies in America by market cap (which combine to make the broader Russell 3000 index), the Russell 2000 gives the most comprehensive snapshot of the small-cap market of any index out there.

What's more, the Russell 2000 is maintained by Russell Investments, a company committed to using rules-based methodologies to construct unbiased indices that differ from the committee-selected Dow Jones Industrial Average or S&P 500.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

More:
Puma Biotechnology Inc (PBYI) Breaks into New 52-Week High on May 30 Session - Equities.com

Share Price and 1 Year Extreme Prices Analysis

The share of Puma Biotechnology, Inc. (PBYI) currently has a value of $78.05 while the companys 52 week low is at $27.64, the shares dropped to the 52 week low on 06/27/16. While the companys share hit the 52 week high on 05/25/17 stationing the value of $75.10.

The difference of 52 week low value as well as 52 week high value and the current price of the stock suggests the next move of the shares. If the share price is currently hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up.

Share Volume Analysis

The volume of the particular stock is the shares bought and sold in a single trading day. The average volume of a stock suggests the liquidity of a particular company. If the average volume is low then the liquidity is low which means it is hard to buy or sell the stock as there are fewer buyers or sellers of the stock.

Currently the shares of Puma Biotechnology, Inc. (PBYI) has the trading volume of 5.7 Million shares with the average trading volume of 5180 shares.

Price to Earnings Ratio

P/E of the company is not reported.

Earnings per Share EPS

Yet another important factor while evaluating a good buy/sell decision for Puma Biotechnology, Inc. (PBYI) is its Earnings per Share or EPS. EPS breaks down the profitability of the company on a single share basis.

Currently, EPS of Puma Biotechnology, Inc. (PBYI) is -1.97 while the analysts predicted the EPS of the stock to be -1.98 suggesting the company fell short of the analysts expectations.

Market Capitalization Analysis

Market Capitalization can be thought of as the overall price to buy the company. Market Capitalization if basically the market value of the companys shares outstanding. Market Cap is also the figure use to determine companys size, as opposed to using sales or total asset figures.

Puma Biotechnology, Inc. (PBYI) has a market capitalization of 2.89 Billion which suggests the company is a huge company further suggesting that the shares of Puma Biotechnology, Inc. (PBYI) are stable and safe compared to the lower market capitalization companies.

Continued here:
Is Puma Biotechnology, Inc. (PBYI) a good buy? - TopChronicle

The stock market performed reasonably well on Friday, sending major benchmarks to gains of 0.25% to 0.5% on the day. Favorable news from the U.S. economy outweighed any concerns about geopolitical events occurring this weekend, including the much-awaited final phase of the French elections. The Dow regained the 21,000 level, and the S&P 500 finished just below the 2,400 mark. But some stocks missed out on the rally, and Puma Biotechnology (NASDAQ:PBYI), Trex (NYSE:TREX), and National CineMedia (NASDAQ:NCMI) were among the worst performers on the day. Below, we'll look more closely at these stocks to tell you why they did so poorly.

Shares of Puma Biotechnology fell 16% after the biotech company said in an SEC filing that an executive in charge of regulatory affairs and project management would resign from the company effective May 15. The filing said that Dr. Robert Charnas had told Puma last week about his departure, with the filing citing health reasons for the move. Yet investors seem to be nervous about the timing, coming immediately before a key advisory panel meeting for its neratinib treatment for breast cancer. Given that neratinib has seen patients in trials report negative side effects, some investors believe that Puma might have trouble getting a positive recommendation from the panel when it meets later this month. The stock's decline might prove to be an overreaction, but the company's decision to put the information in a filing rather than doing a full press release might have contributed to investors' skepticism about the move.

Image source: Trex.

Trex stock declined 9% in the wake of the company releasing its first-quarter financial results. The home deck and railing specialist said that sales climbed 10% from year-ago figures, with increasing margins helping to produce an 18% rise in net income. Trex has gotten a lot of accolades from its industry, including kudos for its environmentally friendly practices and its leadership role in promoting alternatives to traditional wood decking and railing materials. Yet guidance for sales of $160 million in the second quarter only matched investor expectations, and despite calls for improving market share and margin figures, Trex investors seemed to want more from the decking specialist as the high spring season for home improvement begins.

Finally, shares of National CineMedia lost more than a quarter of their value. The in-theater media company said that revenue was down 6% from the year-ago quarter, leading to a drop in operating income and a wider net loss compared to the first quarter of 2016. Despite gains in sales from its local and regional segment as well as its digital and beverage businesses, softness in national advertising revenue weighed on the company's overall results. CEO Andy England reiterated that he sees 2017 as "a transitional year for NCM as we evolve from being the largest cinema network into a truly progressive, integrated digital media company." That means investors have to expect tough results this year, and National CineMedia's guidance called for revenue to fall 1% to 6% and produce a 6% to 12% drop in adjusted operating income. As movie theaters struggle to get people to leave their homes for entertainment, National CineMedia will have to work harder to find new avenues for growth.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Trex. The Motley Fool has a disclosure policy.

See the original post here:
Why Puma Biotechnology, Trex, and National CineMedia Slumped Today - Motley Fool

Plandai Biotechnology Inc (OTCMKTS:PLPL)is a up and coming micro cap, and part of thehealth and wellness craze thats all around us. Every outlet who sells food from McDonalds to the local 7Eleven has healthy food choices. Nearly every menu is shiftingfrom things that taste good to things that make you feel better.

It seems as though nearly all healthy lifestyle enthusiasts take some sort of powdered form of supplement in the morning to start their day, and Plandai is front and center in this lifestyle change. Itsall about science, chemistry and funding as supplements take a step higher as part of our diet. These are all good things for investors as this health lifestyle sector continues its march to higher levels.

It starting to feellike the big four now are cannabis, blockchain/bitcoin, digital media and healthy lifestyle stocks as these sectors mature and begin to break out.

Plandai Biotechnology Inc (OTCMKTS:PLPL) announced last week that its highly bioavailable PhytofareCatechin Complex would be the active ingredient in Capital Brands reformulated and soon-to-be released SuperFood Fat Burning Boost, which is used with the brand NutriBullet. Plandas signature brand Phytofarewill make its way to the U.S. and Europe in Coyne Healthcares product Origine 8.

Coyne Healthcare placed an order for 1.2 million of Plandas Origine 8capsules, which is a product that uses bioavailable green tea extract, PhytofareCatechin Complex, but further enhances the bioavailability of the extract by using an advanced liposome technology developed and clinically validated to improve the delivery of nutritional substances.

Subscribe below and well keep you on top of whats happening before $PLPL stock makes its next move.

Origine 8is a product that entraps all 8 of the catechins of the tea plant, and according to Planda, it is the only catechin-based capsule on the market backed by human clinical studies.

Coyne Healthcare has already been selling Plandas unique product in South Africa, but it now expects to launch Origine 8this month in both the U.S. and Europe. The good news for Planda is that Coyne Healthcare has forecasted sales of 10.6 million Origine 8capsules in 2017, and Coyne expects sales to further increase to 24 million Origine 8capsules in 2018.

Coyne makes its products available through pharmacies, health food stores and medical practitioners, for both NutriBullet and Coyne Healthcare to bring Plandas signature brand to the U.S.

The company also recently announced that it has executed an agreement with Cambridge Commodities Ltd. to become the exclusive Phytofare distributor for the United Kingdom and all of Europe. Based in England, Cambridge Commodities specializes in supplying nutritional ingredients and finished products to the sports nutrition, health and well-being, pet and equine, and food industries.

Under the terms of the agreement, Cambridge Commodities will be required to meet specific quarterly sales goals to retain its exclusive distributor status with the initial quotas being established after a short ramp-up period.

Cambridge Commodities requires all suppliers to complete a verification process consisting of a meticulous questionnaire and thorough sampling of the material before approval. Their technical team, which includes nine professional lead auditors, travel to all parts of the world to ensure products meet all regulatory and quality requirements, and that those products adhere to environmental and social responsibility policies.

Callum Cottrell-Duffield, Vice President of Sales and Marketing for Planda Biotechnology, commented, Cambridge Commodities has been a Planda customer for over a year, so they are very familiar with Phytofare. When the opportunity for a new distributor opened up in the European territory, we all agreed that it would be a perfect partnership. Cambridge has excellent contacts throughout Europe, experienced sales reps, and a great training program. Were confident that they will easily meet and exceed their sales quota and we look forward to working with them.

Shares have done little for Planda Biotechnology(OTCMKTS:PLPL) moving sideways with sporadic volume as the news circulates through the markets. This company looks like it is organizing itself well operationally and is establishing a global footprint for sales, they are also hiring market awareness firms to get the word out about the product and the stock itself. These are all good signs, but the real test will be when shareholders come to buy the stock and need to make a decision between having this be a short term trade or a buy and hold.

We like what we see as this is a sneaky huge growth market for the millennial demographic where funding, sales and solid marketers can grab market share with proper branding. We will add this to our universe of stocks to watch as we have our morning coffee and shake!For more news on PLPLand other fast-moving penny stocks, please subscribe to OracleDispatch.com below.

Read more:
Plandai Biotechnology Inc (OTCMKTS:PLPL) Needs A Millennial Boost - The Oracle Dispatch

Buy, Sell or Hold? Analysts Approach: Innoviva (INVA), Puma ... The USA Commerce Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) dropped -2.02% to $38.90. During the trading on 03/27/2017, Company's stock ranged from $39.70 to ... Puma Biotechnology Inc (NASDAQ:PBYI) Broker Price Targets For ...Fiscal Standard all 3 news articles »

Excerpt from:
Buy, Sell or Hold? Analysts Approach: Innoviva (INVA), Puma ... - The USA Commerce

What happened

Puma Biotechnology(NASDAQ:PBYI) stock has plummeted 18.2% as of 12:53 p.m. EDT following news that Dr. Robert Charnas, its head of regulatory affairs and project management, is hitting the exits ahead of a scheduled Food and Drug Administration (FDA) advisory panel meeting on May 24.

Puma Biotechnology has only one product in its clinical-stage drug pipeline, and that drug, neratinib, has been the subject of a lot of scrutiny after trials showed that a large number of patients taking it suffered from high-grade diarrhea.

Image source: Getty Images.

Puma Biotech's CEO Alan Auerbach hired Charnaslast year to help get neratinib across the regulatory finish line. Previously,Charnas worked at Johnson & Johnson in its research and development department. He was responsible for ongoing development of Zytiga, a prostate cancer drug that J&J acquired in 2009 when it bought Auerbach's previous company, Couger Biotech. Charnas joined Cougar in 2008.

Yesterday, Puma Biotech said Charnas is leaving because of health reasons. However, there's some conflicting information circulating that there may have been some disagreements between him and his co-workers. If so, no one is saying for sure what those disagreements were about.

News of his departure so close to the FDA advisory committee meeting is disconcerting, regardless of Charnas' reasons for leaving.

After all, neratinib is far from a lock to win the committee's recommendation for approval. It's being considered as an extended maintenance therapy to help delay disease recurrence in breast cancer patients who have previously been treated for one year with Herceptin. In trials, neratinib hit its mark in terms of efficacy, but many of its patients reported severe diarrhea.

In hopes of overcoming a rejection because of this safety risk, Puma Biotech has been studying the use of the anti-diarrhea drug loperamide and steroids alongside neratinib. Ideally, a diarrhea incidence rate below 20% would be desirable, but interim trial results showed a 27% rate of grade 3 or higher diarrhea when using loperamide. Steroids may lower that rate further, but their use can cause other unwanted side effects.

It's anyone's guess what will happen at the advisory committee meeting, or what the FDA will ultimately decide to do with neratinib's application. Nevertheless, I think the risk of failure is too high to recommend buying shares ahead of a decision.

Todd Campbell has no position in any stocks mentioned.His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Read the rest here:
Why Puma Biotechnology Shares Are Crashing 18.2% Today - Motley Fool

What happened

Cellect Biotechnology (NASDAQ:APOP), an Israeli-based stem-cell company, today announced the first successful stem cell transplant procedure using its ApoGraft technology in a combined phase 1/2 clinical trial in a blood cancer patient, causing its shares to rise by as much as 115%. The company's stock has since cooled off, but is still up by 80% as of 3:00 p.m. EDT.

Image source: Getty Images.

Even though stem cell transplants can be a curative treatment for many blood disorders and blood-related cancers, they tend to be a treatment of last resort because of their life-threatening side effects, such as graft-versus-host disease (GvHD). So, if Cellect's ApoGraft technology turns out to be a viable workaround, it would be a major advancement in the field, and potentially an extremely lucrative product for the company.

While Cellect's announcement is indeed exciting, its stock still isn't a great long-term bet. Cellect exited 2016 with a paltry $8 million in cash andApoGraft is probably five to six years away from reaching the market. This current trial, after all, is simply a safety and proof-of-concept study that's not designed to provide a basis for a regulatory approval.

In addition, Bellicum Pharmaceuticals'adjunct T-cell therapy BPX-501 could reach the European market as one possible solution to the GvHD problem in blood cancer patients by early 2019, and in the U.S. by perhaps 2020. In other words, Bellicum has a significant head start on Cellect, which may diminish the commercial prospects ofApoGraft moving forward.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Go here to see the original:
Why Cellect Biotechnology Stock Is Skyrocketing Today - Motley Fool

Bank stocks are among the leading laggards as the Dow stares down a possible eighth straight loss. Among specific equities on the move today are biotech stockCellect Biotechnology Ltd. (NASDAQ:APOP), oil services specialistWeatherford International Plc (NYSE:WFT), and steel concernAK Steel Holding Corporation (NYSE:AKS). Here's a quick look at what's moving shares of APOP, WFT, and AKS stock.

Easily topping the Nasdaq's list of gainers today, APOP is surging 67.3% to $10.48 after earlier notching an all-time high at $13.50. Setting the stock on fire is news Cellect Biotechnology Ltd. has completed the first successful stem cell transplant in a blood cancer patient using its ApoGraft technology. The company also received approval from the Data and Safety Monitoring Board (DSMB) to enroll two further patients for similar treatment. APOP has more than doubled in value since its first day of public trading last July, and today's gains could attract attention from the brokerage bunch. At present, just one analyst is covering the stock.

WFT is up 9.5% at $6.45, and is one of the leading percentage gainers on the New York Stock Exchange, after the firm announced a joint venture, OneStim, with Schlumberger Limited. (NYSE:SLB), which will result in a $535 million cash payment to Weatherford International Plc. Today's gains may please options traders, who have taken a heavily call-skewed approach in recent weeks, but short sellers could be headed for the exits. Specifically, short interest on WFT rose by nearly 17% in the most recent two-week reporting period, and now represents 15.2% of the stock's total float -- nearly a week's worth of trading, at the equity's typical daily volume.

As the broad market suffers on concerns over the Trump administration's various promises, including infrastructure spending, AKS is among a slew of metals stocks taking a beating. The shares have given back 3.4% to $6.92, widening their year-to-date deficit to 32.2%, and on track for their lowest close since mid-November. Still, AK Steel Holding Corporation is hanging onto support above the 200-day moving average, which has kept its losses in check for more than a year. That's hardly enough to convince analysts, though. At present, 80% of tracking brokerage firms rate AKS a "hold" or "strong sell."

Visit link:
Cellect Biotechnology, Weatherford, AK Steel Stocks Moving Today - Schaeffers Research (blog)

Biotechnology Gets A Shot In the Arm Barron's The healthcare sector has been doing rather well, gaining 8.9% year-to-date. Behind just information technology, healthcare stocks have outpaced Trump sectors including materials, industrials, and financials so far, suggesting that investors may be ... iShares Nasdaq Biotechnology (IBB) volatility low into Credit Suisse upgrade from Market Weight to OverweightStreetInsider.com iShares NASDAQ Biotechnology Index - Receive News & Ratings DailyBBNS all 5 news articles »

Visit link:
Biotechnology Gets A Shot In the Arm - Barron's

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Agricultural Biotechnology: Emerging Technologies and Global Markets" report to their offering.

The study scope includes key agricultural biotechnology tools (i.e., next generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genome editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

These technologies and products are analyzed to determine present and future market sizes, and forecasted growth from 2017 through 2022. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status, and market driving forces.

In-depth coverage of the agricultural biotechnology industry structure is provided, including genomics technology providers (e.g., genome editing, NGS, microarray companies); major seed companies; biotech traits companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2015 and 2016.

Scope of the Report:

Companies Mentioned

Key Topics Covered:

1: Introduction

2: Executive Summary

3: Overview

4: Technologies

5: Market Applications

6: Agricultural Biotechnology Industry

7: Markets

8: Patents

9: Company Profiles

For more information about this report visit http://www.researchandmarkets.com/research/hc5mtg/agricultural

View source version on businesswire.com: http://www.businesswire.com/news/home/20170324005422/en/

See more here:
Agricultural Biotechnology - Emerging Technologies & Global ... - Yahoo Finance

The 66 rating InvestorsObserver gives to Esperion Therapeutics Inc (ESPR) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 85 percent of stocks in the Biotechnology industry, ESPRs 66 overall rating means the stock scores better than 66 percent of all stocks.

Click Here to get the full Stock Score Report on Esperion Therapeutics Inc (ESPR) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Esperion Therapeutics Inc (ESPR) stock has gained 7.95% while the S&P 500 has fallen -0.25% as of 11:33 AM on Friday, Feb 7. ESPR has gained $4.61 from the previous closing price of $57.98 on volume of 444,201 shares. Over the past year the S&P 500 is higher by 23.33% while ESPR has gained 38.57%. ESPR lost -$3.69 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Originally posted here:
Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? - InvestorsObserver

The Global Separation Systems For Commercial Biotechnology Market report offers compound growth from the base year and projected until 2026. The report prepared on the basis of an in-depth analysis of the market that lights shed on the market with a vision to provide a general overview of the market. The report is further fragmented on the basis of segmentation that involves product type, application, and geography. Esticast Research and Consulting provides accurate market size and forecast in relation to the major five regions. The report further evaluates various opportunities and trends to prove superior in the market.

About Separation Systems For Commercial Biotechnology Market

Biological products have a significant importance in various range of sectors such as food, cosmetic and pharmaceutical industries. Bioseparation purifies biological products on a largescale. The global separation systems for commercial biotechnology market is driven by increasing demand for novel drug molecules and cell-based therapies and commercial separation systems in the biotechnology industry. Additionally, increased participation of government agencies, rising number of biotech firms, and investment in research & development of the technology and growing demand for microarray technology are some other factors which are contributing to the market growth. Mergers, acquisition and expansion are the key strategies adopted by the major market players of separation systems for commercial biotechnology market.

For Better Understanding, Try Sample PDF Brochure of Report (including full TOC, Tables and Figures) @https://www.esticastresearch.com/report/separation-systems-commercial-biotechnology-market/#request-for-sample

Market Overview

The research report covers various developments across the geography of the Separation Systems For Commercial Biotechnology market based on the tools of organic as well as inorganic growth strategies. The Separation Systems For Commercial Biotechnology market report is capable enough to project and present data till 2026 on the basis of the global market trend. The market report presented provides key statistics based on the past and current status of the market coupled with key trends and opportunities.

The report not only analyses factors responsible for impacting the Separation Systems For Commercial Biotechnology market on the basis of the value chain but also evaluates industry forces that will highlight the market in the coming years. The industry forces include stumbling blocks, drivers, challenges, and opportunities. The report is also providing in-depth insights on the basis of secondary tools such as SWOT, Porters Five Force Analysis, and PEST. The secondary based tools cover a wide spectrum of regions but focuses on key regions that include North America, Europe, Asia Pacific, Middle East, South America, and the Middle East & Africa (MEA).

What the report features:

List of the Key Players of Separation Systems For Commercial Biotechnology :

Company 1Company 2And Many More

Key players mentioned in the report are based on the secondary research tool. The market share of the company is based on both primary as well as secondary based research. All shares have been presented in a precise fashion that has been determined using several resources.

The competitive landscape chapter is enlisted separately which proves as a supporting agent. The chapter sheds light and provides a visual presentation of the key players. In addition, the report also covers the designing of several strategies that are adopted by the key participants to lead the race in the long run. Various strategies include coverage of M&A, new product launch, setting up R&D team, development of infrastructure, and among others.

Market Segmentation

On the basis of types, the global Separation Systems For Commercial Biotechnology market is fragmented into

Membrane FiltersFlow CytometerDNA MicroarrayProtein MicroarrayMACS & FACS SystemsCentrifugation SystemsLiquid ChromatographyElectrophoresis UnitsOthers (biochips, lab-on-a-chip, etc.)

Based on applications, the global Separation Systems For Commercial Biotechnology market is split into:

Food & CosmeticsAgricultureEnergyLife Sciences ResearchPharmaceuticals

Inquire more or share questions if any before the purchasing this report: https://www.esticastresearch.com/report/separation-systems-commercial-biotechnology-market/#customization

The years that were considered for the study of this report are the following:

Key Benefits:

Navale ICON IT Park,

Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, Pune

Maharashtra 411041

Phone +91-844-601-6060

Email [emailprotected]

Esticast Research & Consulting is a research firm providing research reports on various industries with a unique combination of authenticity, extensive research, and infallibility. We provide syndicated market research reports, customization services, and consulting services to help businesses across the world in achieving their goals and overcoming complex challenges. We specialize in providing 360 degree view of the markets to assist clients in determining new opportunities and develop business strategies for the future with data and statistics on changing market dynamics. Esticast Research & Consulting has expert analysts and consultants with an ability to work in collaboration with clients to meet their business needs and give opportunities to thrive in a competitive world. A comprehensive analysis of industries ranging from healthcare to consumer goods and ICT to BFSI is provided by covering hundreds of industry segments. The research reports offering market forecasts, market entry strategies, and customer intelligence will help clients across the world in harnessing maximum value on their investment and realize their optimum potential.

See the original post:
Separation Systems For Commercial Biotechnology Market Trends, Growth Opportunities, Key Vendors, Growth, Analysis, Outlook & Forecasts To 2026|...

Ross Murdoch has been the CEO of Avecho Biotechnology Limited (ASX:AVE) since 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look at a snap shot of the business growth. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to consider the appropriateness of CEO pay levels.

Check out our latest analysis for Avecho Biotechnology

Our data indicates that Avecho Biotechnology Limited is worth AU$7.9m, and total annual CEO compensation was reported as AU$404k for the year to December 2018. We think total compensation is more important but we note that the CEO salary is lower, at AU$351k. We examined a group of similar sized companies, with market capitalizations of below AU$289m. The median CEO total compensation in that group is AU$379k.

So Ross Murdoch receives a similar amount to the median CEO pay, amongst the companies we looked at. This doesn't tell us a whole lot on its own, but looking at the performance of the actual business will give us useful context.

You can see a visual representation of the CEO compensation at Avecho Biotechnology, below.

ASX:AVE CEO Compensation, January 14th 2020

On average over the last three years, Avecho Biotechnology Limited has grown earnings per share (EPS) by 65% each year (using a line of best fit). It achieved revenue growth of 310% over the last year.

This shows that the company has improved itself over the last few years. Good news for shareholders. Most shareholders would be pleased to see strong revenue growth combined with EPS growth. This combo suggests a fast growing business. Although we don't have analyst forecasts shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.

With a three year total loss of 80%, Avecho Biotechnology Limited would certainly have some dissatisfied shareholders. This suggests it would be unwise for the company to pay the CEO too generously.

Ross Murdoch is paid around what is normal the leaders of comparable size companies.

We think that the EPS growth is very pleasing, but we find the returns over the last three years to be lacking. We'd be surprised if shareholders want to see a pay rise for the CEO, but we'd stop short of calling their pay too generous. CEO compensation is one thing, but it is also interesting to check if the CEO is buying or selling Avecho Biotechnology (free visualization of insider trades).

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Go here to read the rest:
Should You Be Pleased About The CEO Pay At Avecho Biotechnology Limited's (ASX:AVE) - Yahoo Finance

Innovation-driven biotechnology companies are all set to generate profit in the future years by executing value-based business and marketing strategies.

FREMONT, CA: Today, the availability of a broader range of high-tech applications has contributed to transforming the biotechnology industry. From physical examinations to smartly extracting information, emerging innovations help biotechnologists explore new methods to enable market expansion. Some of such trends revolutionizing the biotechnology sphere are listed below.

Digitally Driven Research

Adopting technology-based tools and applications help the modern-day professionals tackle market challenges by delivering the quality, safety, and efficacy of biotechnology products and services. The changing biotechnology demands can be achieved by upgraded tools and applications to perform researches in an advanced and instant manner. In recent years, biotechnology companies prefer digital research infrastructure, which enables them to collaborate with different experts from numerous locations and successfully examine bio components and properties.

Commercial Value-Based Pricing

It is high time for biotechnology products and service providers to set value-based pricing arrangements. The rising commercialization has increased the revenue streams; biotechnology providers can take advantage of data analytics to track customer demands and predict future market scenarios for strategically making decisions on different product pricing before the launch. Such a pricing arrangement can frame the real-time and measurable value of the biotechnology companies while attracting more stakeholders to invest in.

Automatic Conformance to Regulations

The rapidly advancing biotechnology companies need to follow different rules and regulations for testing and trading drugs. Tech-driven operational infrastructures offer smart features like automatically upgrading operational processes according to the upgraded rules and sending alerts regarding new regulations across the organization. Technology delivers the ability to access massive information from multiple resources for performing data-driven research processes.

With technology creating brilliant business opportunities, innovative solutions for biotechnology companies help the developments in genomics, proteomics, drug discovery, and more. The increasing pace of tech interventions in the industrial ecosystem has encouraged many investors to support biotechnology companies.

See the original post here:
Where Is The Biotech Market Heading? - CIO Applications

David P. Clark did his graduate work on bacterial antibiotic resistance to earn his Ph.D. from Bristol University, in the West of England. During this time, he visited the British Government's biological warfare facility at Porton Down and was privileged to walk inside the (disused) Black Death fermenter. He later crossed the Atlantic to work as a postdoctoral researcher at Yale University and then the University of Illinois. David Clark recently retired from teaching Molecular Biology and Bacterial Physiology at Southern Illinois University which he joined in 1981. His research into the Regulation of Alcohol Fermentation in E. coli was funded by the U.S. Department of Energy, from 1982 till 2007. From 1984-1991 he was also involved in a project to use genetically altered bacteria to remove contaminating sulfur from coal, jointly funded by the US Department of Energy and the Illinois Coal Development Board. In 1991 he received a Royal Society Guest Research Fellowship to work at Sheffield University, England while on sabbatical leave. He has supervised 11 masters and 7 PhD students and published approximately 70 articles in scientific journals. He has written or co-authored several textbooks, starting with Molecular Biology Made Simple and Fun (with Lonnie Russell; (Cache River Press, First edition, 1997) which is now in its fourth edition. Other books are Molecular Biology and Biotechnology (both published by Elsevier) He recently wrote a popular science book, Germs, Genes, & Civilization: How Epidemics Shaped Who We Are Today (2010, Financial Times Press/Pearson). David is unmarried, but his life is supervised by two cats, Little George and Mr Ralph.

Nanette J. Pazdernik, Ph.D. is a co-author of Biotechnology, 2nd edition and Molecular Biology, 2nd edition, with Dr. David Clark. The second edition of Molecular Biology won a Texty award from the Textbook and Academic Authors Association in 2013. She has also authored an on-line study guide to accompany the update edition of Molecular Biology. She has taught courses in General Biology, Genetics, as well as Anatomy and Physiology at Southwestern Illinois College, McKendree University, and Harris-Stowe University. She received her BA in Biology from Lawrence University in Appleton, Wisconsin, in 1990 and her PhD in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota in 1996. Her doctoral thesis studied how alterations in the structure of lactose permease affect its ability to transport sugar across the membrane of E. coli. Following her degrees, she investigated the IL-1 and TNF signal transduction pathways that control apoptosis and immunity at Indiana University School of Medicine. She has most recently studied the various molecules that maintain the stem cell fate in C. elegans at Washington University School of Medicine in St. Louis, MO. She is married and the mother of three children, ages 15, 12, and 8, which always make her realize the role biology plays in personality and development!

More here:
Biotechnology: David P. Clark BA (honors)Christ's College ...

UNITY Biotechnology, a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, announced the closing of an additional$35 millionin Series B financing. This second close of the Series B, in addition to the initial close infall of 2016, brings the total amount of this financing to$151 million.

The UNITY Series B financing ranks among the largest private financings in biotech history. New Series B investors include INVUS Opportunities, Three Lakes Partners, Cycad Group, COM Investments, and Pivotal Alpha Limited.These new investors join the Series B led by longtime life science investors ARCH Venture Partners, Baillie Gifford, Fidelity Management and Research Company, Partner Fund Management, and Venrock. Other investors include Bezos Expeditions, Vulcan Capital, Founders Fund, WuXi PharmaTech, and Mayo Clinic Ventures. Proceeds from this financing will be used to expand ongoing research programs in cellular senescence and advance the first preclinical programs into human trials.

UNITYalsoannounced thatGraham Cooperhas joined UNITY's board of directors. Mr. Cooper was previously the chief financial officer ofReceptos,which was acquired by Celgene in 2015 for$7.8 billion.

"We are incredibly fortunate to have attracted someone of Graham's experience and judgment to help us shape our mission of attacking diseases of aging and fundamentally reshaping human healthspan," saidKeith Leonard, UNITY chairman and CEO. "The incredible investor support matched with the progress in preclinical development has us on track to initiate clinical trials in 2018 with our first senolytic drug."

"UNITY pairs a huge market opportunity with highly compelling biology and a proven and experienced management team. We continue to attract both a highly skilled team and deep financial backing to match the potential," saidRobert Nelsen, UNITY board member and co-founder and managing director of ARCH Venture Partners, UNITY's founding investor.

Originally posted here:
UNITY Biotechnology Announces Series B Financing Extension ... - Drug Discovery & Development

For years, the international community has grappled with the threat of chemical, biological, radiological, and nuclear terrorism. And although al Qaeda and the Islamic State (ISIS) have demonstrated interest in and some capability to develop and use such weapons, there have been no successful mass casualty terrorist attacks involving them. Attempted attacks involving radiological dispersal devices or chemical and biological means have either failed or had a very limited impact. Experts such as John Parachini, Jeffrey Bale and Gary Ackerman, Adam Dolnik, and Rajesh Basrur and Mallika Joseph argue that the reason is terrorists inability to weaponize chemical, biological, radiological, or nuclear material. Others, including Brian Michael Jenkins, believe that the lack of mass causality attacks also has to do with self-restraint: perpetrators might not be able to control the consequences of such an attack. It could end up harming the members of the communities that the terrorists are purportedly fighting for and could therefore be counterproductive.

The recent WannaCry ransomware attack, however, could force the expert community to rethink such positions. Although available information suggests that North Korean hackers were behind these attacks, in which hackers took control of about 300,000 computers in over 150 countries and held the victims hostage in exchange for a payment of $300 in bitcoin, there is reason to believe that terrorist groups such as al Qaeda and ISIS could copy the tactic. In doing so, they would cause as much damage (loss of data and equipment) and chaos (in hospitals and other public utilities) as possible, comparable to the chaos and panic that could be caused by a chemical or biological attack.

Terrorists could use cyber capabilities to target any sector. But the most vulnerable industries are those with high proportions of old infrastructure onto which new technology has been grafted. According to a report from the U.S. Bureau of Economic Analysis, in 2015, the average age of all fixed assets in the United States stood at 22.8 years, with hospitals and utilities some of the worst culprits.

Follow this link:
Cyberterrorism and Biotechnology - Foreign Affairs (subscription)